SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51803I listened to most of the meeting, except for the first hour or so. My impressiArt Bechhoefer-7/15/2021
51802So where do they go from here? Sounds like the panel would like limited approvalJamesK-7/15/2021
51801I was fearing this drubbing at the committee, kicking myself for missing reducinA.J. Mullen-7/15/2021
51800The advisory panel of 14 members voted NO on approval of roxadustat for both diaArt Bechhoefer-7/15/2021
51799I can no longer find this briefing paper on roxadustat fda.gov produced by FDA sA.J. Mullen-7/15/2021
51798Thanks for the research you did to discover why there could be an approval issueArt Bechhoefer-7/14/2021
51797I didn't know the treasure trove was available. Thanks. fda.gov. It'sA.J. Mullen-7/14/2021
51796Roxadustat demonstrated comparable CV safety to placebo in patients with NDD CKDdiegosan27/14/2021
51795The price of NTLA shares is currently about 19 times book value. Almost the entArt Bechhoefer27/12/2021
51794I had been planning on buying some Intellia to complement my CRISPR TherapeuticsFrank Sully-7/11/2021
51793Where Will ARK Genomic Revolution ETF Be in 5 Years? Cathie Wood's genomicsFrank Sully-7/11/2021
51792CRSP Up 15.6/% This Week In Sympathy with Intellia. Now my CRSP position is upFrank Sully-6/30/2021
51791It'll be years and more than six patients before approval. Onpattro is deliA.J. Mullen-6/28/2021
51790Yes it's all euphoria now. I see this taking awhile to play out. First of coJamesK-6/28/2021
51789Congratulations if you hold NTLA. Within 30 mins of opening it's up 48%, CRA.J. Mullen-6/28/2021
51788Thanks for alerting us to that. Editing genes in vivo suggest the procedure migA.J. Mullen-6/26/2021
51787You had asked about gene therapy vs. ALNY approach. NTLA is out with results todJamesK16/26/2021
51786Thanks for laying out your thinking. You’re valuing a fully approved FGEN in thA.J. Mullen-6/25/2021
51785The reason for my low range $40 – $60 target for the remainder of this year has Art Bechhoefer16/25/2021
51784Thanks again. Given the stock has already exceeded $60 before any approval in EA.J. Mullen16/25/2021
51783There is further detail on a GlobalNewswire on the Yahoo FibroGen web site. AstArt Bechhoefer-6/25/2021
51782Astellas! Thanks for the correction. Do you know what the split is in Europe aA.J. Mullen-6/25/2021
51781Roxadustat is a lower cost treatment than any of the erythropoietin drugs it wilArt Bechhoefer-6/25/2021
51780Has anyone seen an estimate of the value sales of roxadustat to FGEN by region? A.J. Mullen-6/25/2021
51779EU committee is recommending approval for roxadustat, seekingalpha.com, and yet A.J. Mullen-6/25/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News